Broad-Spectrum Potential to Treat and Prevent Infectious Diseases: Peregrine Pharmaceuticals PS-Targeting Antibodies

Recent years have seen a surge in scientific publications investigating the occurrence of exposed phosphatidylserine (PS) during the infections caused by viruses and protozoan parasites. These groups of pathogens are responsible for many of the deadliest and most widespread diseases affecting mankind including AIDS and malaria.

Peregrine's PS targeting antibodies may address a common immune evasion mechanism exploited by infectious pathogens. Exposed PS is a subject of increasing study by researchers worldwide as a result of its thoroughly documented immunosuppressive activity, its active role in numerous infections, and its potential as a valid broad-spectrum therapeutic target.

Peregrine's PS targeting Infectious Disease Research Program represents a rapidly growing segment of the company that has achieved significant progress and is now well-positioned to generate extensive and broad data through a large number of collaborations with leading research institutions worldwide.

Peregrine's PS-Targeting Infectious Disease Program: Milestones to date

• Clinical stage antiviral program with two completed HCV clinical trials with positive signs of antiviral activity. An additional HCV/HIV co-infection trial is ongoing.
  
  
• Bio-defense research contract with the U.S. Defense Threat Reduction Agency worth up to $44.4 million to assess PS targeting antibodies as treatment and prevention of multiple viral hemorrhagic fever infections.
  
  
• Recent publication in the journal Nature Medicine supporting broad-spectrum antiviral activity of PS targeting antibodies against lethal viral infections in animals.
  
  
• Strategic research collaborations with leading U.S. and international institutions utilizing government and thirdparty funding to evaluate Peregrine's PS targeting antibodies in therapeutic, vaccine, and topical microbicide regimens against a diverse set of viruses and other deadly pathogens.
  
  
• Several U.S. and international issued patents and allowed applications establishing intellectual property leadership in the emerging field of PS targeting therapeutics for the treatment of life-threatening infections. For example, U.S. Patent # 7,455,833.